Cln2 Disease

• FDA approval · 2018-12-11
  FDA Approved: BRINEURA — Supplemental Application (BioMarin Pharmaceutical Inc.)

  The FDA approved a supplemental application for BRINEURA (cerliponase alfa) from BioMarin Pharmaceutical Inc., updating the drug’s approved …

• CLINICAL_TRIALS approval · 2017-07-24
  Clinical Trial Update: A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

  Marketing approval granted for BioMarin's BMN 190 (cerliponase alfa) to treat CLN2 disease; the therapy is now approved for marketing.